Deprescribing Low-Dose Quetiapine for Insomnia: A Provider’s Guide
Low-dose quetiapine for insomnia has weak evidence and real metabolic risk. How providers can confirm the indication, stop or taper, and replace it with…
Evidence-based clinical resources for providers (physicians, nurse practitioners, physician assistants, pharmacists) on safer medication deprescribing.
Low-dose quetiapine for insomnia has weak evidence and real metabolic risk. How providers can confirm the indication, stop or taper, and replace it with…
How prescribing cascades start, which nine pairs to look for first, what the harm data show, and how to unwind one without destabilizing the…
Provider guide to deprescribing antihypertensives in older adults: who qualifies, what OPTIMISE and Cochrane show, what to stop first, how to monitor.
Medication overuse headache: ICHD-3 thresholds, which drug classes carry the most risk, how to taper by class, and what the MOTS trial changed.
When allopurinol can be safely withdrawn, when it should not be, and a stepwise protocol with urate monitoring and restart criteria.
How to reduce antipsychotic polypharmacy to monotherapy: what the randomized trials show, which combinations to protect, and a tested taper pace.
A provider's guide to reviewing and deprescribing fall-risk-increasing drugs after a fall: STOPPFall classes, taper rules, monitoring, and the evidence.
Evidence, candidate selection, taper schedules, relapse planning and CMS gradual dose reduction rules for deprescribing antipsychotics in dementia.
What the AAN advisory and NICE NG217 ask of providers before withdrawing antiseizure medication in seizure-free adults: risk, taper rate and driving.
What the Shed-MEDS, MedSafer and OPERAM trials show about deprescribing at hospital discharge, and how to write the handoff so the change holds.